[{"id":"171aed28-1c95-4308-9517-1d8f94969861","acronym":"","url":"https://clinicaltrials.gov/study/NCT00788684","created_at":"2021-01-18T02:59:25.635Z","updated_at":"2025-02-25T13:51:53.765Z","phase":"Phase 1","brief_title":"Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers","source_id_and_acronym":"NCT00788684","lead_sponsor":"AbbVie","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/21/2009","start_date":" 07/21/2009","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-20"},{"id":"0829dd6e-d56c-4a78-8e9f-bd6b6b2da23c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02079740","created_at":"2021-01-18T09:35:19.928Z","updated_at":"2025-02-25T15:33:04.083Z","phase":"Phase 1/2","brief_title":"Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02079740","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • NRAS • BCL2L2","pipe":" | ","alterations":" KRAS mutation • NRAS mutation","tags":["KRAS • NRAS • BCL2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • navitoclax (ABT 263) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/26/2014","start_date":" 03/26/2014","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-11"},{"id":"c84b4894-7b72-40e5-b7d9-73619eecd885","acronym":"22P.205","url":"https://clinicaltrials.gov/study/NCT05564650","created_at":"2022-10-03T15:56:48.447Z","updated_at":"2025-02-25T15:35:52.261Z","phase":"Phase 1/2","brief_title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05564650 - 22P.205","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2025-02-11"},{"id":"577a4268-ea8b-44ef-b557-7019f2e329c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691504","created_at":"2023-01-20T16:00:14.081Z","updated_at":"2025-02-25T16:46:30.558Z","phase":"Phase 1","brief_title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","source_id_and_acronym":"NCT05691504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • BCL2L1","pipe":"","alterations":" ","tags":["BRAF • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-05"},{"id":"0ddf2dab-b38d-4054-a616-48669cd75157","acronym":"","url":"https://clinicaltrials.gov/study/NCT02143401","created_at":"2021-01-18T09:57:19.810Z","updated_at":"2024-07-02T16:35:01.909Z","phase":"Phase 1","brief_title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT02143401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • AFP • CASP3","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1 • AFP • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2014","start_date":" 11/07/2014","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 05/20/2025","study_completion_date":" 05/20/2025","last_update_posted":"2024-05-22"},{"id":"cfc2985f-51c4-4ab9-8232-962b73ff7481","acronym":"NCI-2013-02103","url":"https://clinicaltrials.gov/study/NCT01989585","created_at":"2021-01-18T09:04:22.279Z","updated_at":"2024-07-02T16:35:03.325Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","source_id_and_acronym":"NCT01989585 - NCI-2013-02103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • BCL2","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K","tags":["PTEN • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/24/2014","start_date":" 03/24/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"},{"id":"8e698f4d-2a78-42c5-a620-76e572d7431e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595059","created_at":"2021-01-18T17:40:37.713Z","updated_at":"2024-07-02T16:35:05.958Z","phase":"Phase 1","brief_title":"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors","source_id_and_acronym":"NCT03595059","lead_sponsor":"AbbVie","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-03"},{"id":"500cdb1b-cc26-4d01-947d-9f667ab8c48a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04771572","created_at":"2021-02-25T15:52:22.502Z","updated_at":"2024-07-02T16:35:07.720Z","phase":"Phase 1","brief_title":"Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.","source_id_and_acronym":"NCT04771572","lead_sponsor":"Newave Pharmaceutical Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LP-118"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-04-24"},{"id":"721fdaab-3a1b-4137-ac76-da3bdf51d631","acronym":"","url":"https://clinicaltrials.gov/study/NCT04893759","created_at":"2021-05-19T11:52:44.705Z","updated_at":"2024-07-02T16:35:22.677Z","phase":"Phase 1","brief_title":"A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors","source_id_and_acronym":"NCT04893759","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" BCL2L2","pipe":"","alterations":" ","tags":["BCL2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-23"},{"id":"63d174f5-1045-41f8-a030-f399abb4d1dd","acronym":"NCI-2016-00073","url":"https://clinicaltrials.gov/study/NCT02697344","created_at":"2021-01-18T13:10:03.223Z","updated_at":"2024-07-02T16:35:25.022Z","phase":"Phase 1","brief_title":"Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma","source_id_and_acronym":"NCT02697344 - NCI-2016-00073","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • CRBN • MAPK1","pipe":" | ","alterations":" BCL2 expression • CRBN expression","tags":["BCL2 • CRBN • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • CRBN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/14/2016","start_date":" 04/14/2016","primary_txt":" Primary completion: 10/26/2018","primary_completion_date":" 10/26/2018","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2023-12-28"},{"id":"2a514802-0bd5-42d1-abc9-294d1a4f3448","acronym":"","url":"https://clinicaltrials.gov/study/NCT06133088","created_at":"2023-11-15T19:16:06.349Z","updated_at":"2024-07-02T16:35:29.099Z","phase":"Phase 2","brief_title":"Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.","source_id_and_acronym":"NCT06133088","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" CDK6 • LRPPRC","pipe":"","alterations":" ","tags":["CDK6 • LRPPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • R-(-)-gossypol (AT 101)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-11-15"},{"id":"759ba1b6-e6e6-4f22-81f3-e0016eb2b1d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01633541","created_at":"2021-01-18T07:01:11.806Z","updated_at":"2024-07-02T16:35:42.408Z","phase":"Phase 2","brief_title":"Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer","source_id_and_acronym":"NCT01633541","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • docetaxel • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 11/06/2021","primary_completion_date":" 11/06/2021","study_txt":" Completion: 11/06/2021","study_completion_date":" 11/06/2021","last_update_posted":"2023-07-20"},{"id":"e8364154-5f9c-4369-9f67-2f27cf14b864","acronym":"Exactis-03","url":"https://clinicaltrials.gov/study/NCT05358639","created_at":"2022-05-03T14:54:00.785Z","updated_at":"2024-07-02T16:35:43.607Z","phase":"Phase 1","brief_title":"Combination of Olaparib and Navitoclax in Women With HGSC and TNBC","source_id_and_acronym":"NCT05358639 - Exactis-03","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • navitoclax (ABT 263)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/09/2022","start_date":" 11/09/2022","primary_txt":" Primary completion: 04/28/2024","primary_completion_date":" 04/28/2024","study_txt":" Completion: 04/28/2025","study_completion_date":" 04/28/2025","last_update_posted":"2023-07-07"},{"id":"6b450ba8-fa67-4a5f-912d-deea4c078553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05025358","created_at":"2021-08-27T12:53:06.976Z","updated_at":"2024-07-02T16:36:02.645Z","phase":"Phase 1","brief_title":"A Study of LP-118 in Patients With Advanced Tumors","source_id_and_acronym":"NCT05025358","lead_sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LP-118"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2022-10-11"},{"id":"00d40478-682a-4afc-87d8-0de2d98dbcc1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03080311","created_at":"2021-01-18T15:10:26.131Z","updated_at":"2024-07-02T16:36:07.402Z","phase":"Phase 1","brief_title":"A Study of APG-1252 in Patients With SCLC or Other Solid Tumors","source_id_and_acronym":"NCT03080311","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" BCL2L2","pipe":"","alterations":" ","tags":["BCL2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pelcitoclax (APG-1252)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/12/2017","start_date":" 02/12/2017","primary_txt":" Primary completion: 06/22/2020","primary_completion_date":" 06/22/2020","study_txt":" Completion: 07/17/2020","study_completion_date":" 07/17/2020","last_update_posted":"2022-07-12"},{"id":"7884f7af-1265-4ccd-be78-fa2be8ed7aa3","acronym":"ITALLI001","url":"https://clinicaltrials.gov/study/NCT05054465","created_at":"2021-09-23T17:53:03.625Z","updated_at":"2024-07-02T16:36:24.048Z","phase":"Phase 1b","brief_title":"A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL","source_id_and_acronym":"NCT05054465 - ITALLI001","lead_sponsor":"Israeli Medical Association","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • navitoclax (ABT 263)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2021-09-23"},{"id":"59c6f80d-6c97-43c5-b861-beaa6fc54bec","acronym":"MONAVI-1","url":"https://clinicaltrials.gov/study/NCT02591095","created_at":"2021-01-18T12:34:30.643Z","updated_at":"2024-07-02T16:37:01.571Z","phase":"Phase 2","brief_title":"A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02591095 - MONAVI-1","lead_sponsor":"Centre Francois Baclesse","biomarkers":" BCL2L11","pipe":"","alterations":" ","tags":["BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-03-19"},{"id":"b970ecd8-479e-4b6a-a06f-d62c63791089","acronym":"","url":"https://clinicaltrials.gov/study/NCT00445198","created_at":"2021-01-18T01:34:22.525Z","updated_at":"2024-07-02T16:37:10.250Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies","source_id_and_acronym":"NCT00445198","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2018-06-06"},{"id":"3a95cb99-a207-4584-bf34-fd1b90df2dbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00540722","created_at":"2021-01-18T01:57:56.081Z","updated_at":"2024-07-02T16:37:18.969Z","phase":"Phase 2","brief_title":"Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme","source_id_and_acronym":"NCT00540722","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2017-08-11"}]